M
Margaret M. Billingsley
Researcher at University of Pennsylvania
Publications - 22
Citations - 3148
Margaret M. Billingsley is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 10, co-authored 15 publications receiving 700 citations. Previous affiliations of Margaret M. Billingsley include University of Delaware.
Papers
More filters
Journal ArticleDOI
Engineering precision nanoparticles for drug delivery
Michael J. Mitchell,Margaret M. Billingsley,Rebecca M Haley,Marissa E. Wechsler,Nicholas A. Peppas,Robert Langer +5 more
TL;DR: Advances in nanoparticle design that overcome heterogeneous barriers to delivery are discussed, arguing that intelligent nanoparticles design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.
Journal ArticleDOI
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.
Margaret M. Billingsley,Nathan Singh,Pranali Ravikumar,Rui Zhang,Carl H. June,Michael J. Mitchell +5 more
TL;DR: The ability of ionizable LNPs to deliver mRNA to primary human T cells for functional protein expression is demonstrated and the potential of LNPS to enhance mRNA-based CAR T cell engineering methods is indicated.
Journal ArticleDOI
Biomaterials for vaccine-based cancer immunotherapy.
TL;DR: The rational design and clinical status of several classes of cancer vaccines are discussed along with novel biomaterial‐based delivery technologies that improve their safety and efficacy.
Journal ArticleDOI
Nanomaterials for T-cell cancer immunotherapy.
TL;DR: In this article, an overview of nanomaterials that have been used to overcome clinical barriers to T-cell-based immunotherapies and provide an outlook of this emerging field at the interface of cancer immunotherapy and Nanomaterial design.
Journal ArticleDOI
Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening
Pedro P.G. Guimarães,Rui Zhang,Roman Spektor,Mingchee Tan,Amanda Chung,Margaret M. Billingsley,Rakan El-Mayta,Rachel S. Riley,Lili Wang,James M. Wilson,Michael J. Mitchell +10 more
TL;DR: This platform, which enables direct barcoding and subsequent quantification of a functional mRNA itself, can accelerate the in vivo screening and design of LNPs for mRNA therapeutic applications such as CRISPR/Cas9 gene editing, mRNA vaccination, and other mRNA-based regenerative medicine and protein replacement therapies.